MX2018001173A - Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. - Google Patents

Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.

Info

Publication number
MX2018001173A
MX2018001173A MX2018001173A MX2018001173A MX2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A
Authority
MX
Mexico
Prior art keywords
modulators
compounds useful
tnf alpha
cyclic compounds
compounds
Prior art date
Application number
MX2018001173A
Other languages
English (en)
Spanish (es)
Inventor
Xiao Hai-Yun
Jiang Bin
Duan Jingwu
T G Dhar Murali
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018001173A publication Critical patent/MX2018001173A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2018001173A 2015-08-03 2016-08-02 Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. MX2018001173A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200415P 2015-08-03 2015-08-03
PCT/US2016/045104 WO2017023902A1 (en) 2015-08-03 2016-08-02 Cyclic compounds useful as modulators of tnf alpha

Publications (1)

Publication Number Publication Date
MX2018001173A true MX2018001173A (es) 2018-04-24

Family

ID=56610045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001173A MX2018001173A (es) 2015-08-03 2016-08-02 Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.

Country Status (13)

Country Link
US (1) US10335392B2 (https=)
EP (1) EP3331889B1 (https=)
JP (1) JP6811233B2 (https=)
KR (1) KR102679517B1 (https=)
CN (1) CN108137609B (https=)
AU (1) AU2016301215A1 (https=)
BR (1) BR112018001980A2 (https=)
CA (1) CA2994703A1 (https=)
EA (1) EA201890421A1 (https=)
ES (1) ES2828696T3 (https=)
IL (1) IL257159A (https=)
MX (1) MX2018001173A (https=)
WO (1) WO2017023902A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288939A1 (en) 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
EP4556478A4 (en) * 2022-08-08 2025-10-22 Medinno Pharmaceutical Tech Zhuhai Co Ltd TGF-BETA INHIBITOR COMPOUND AND USE THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5149386A (ja) * 1974-10-28 1976-04-28 Hitachi Ltd Shuchukanshiseigyohoho
CA2281927C (en) 1997-02-25 2004-01-27 Christopher J. Michejda Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
JPH11228539A (ja) * 1997-12-03 1999-08-24 Taisho Pharmaceut Co Ltd 含窒素四環性化合物
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
JPWO2003064422A1 (ja) 2002-01-31 2005-05-26 第一製薬株式会社 イミダゾ[1,2−a]ピリジン誘導体
AU2003298839A1 (en) 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
CN103739605B (zh) 2009-03-23 2016-08-17 伊莱利利公司 用于检测神经障碍的显像剂
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
KR101669334B1 (ko) * 2013-09-30 2016-10-25 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9920052B2 (en) 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
RU2685234C1 (ru) 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
CN107635993B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 取代的三环杂环化合物
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf

Also Published As

Publication number Publication date
EP3331889A1 (en) 2018-06-13
ES2828696T3 (es) 2021-05-27
JP6811233B2 (ja) 2021-01-13
BR112018001980A2 (pt) 2018-09-18
IL257159A (en) 2018-03-29
US10335392B2 (en) 2019-07-02
WO2017023902A1 (en) 2017-02-09
KR20180031773A (ko) 2018-03-28
US20180221344A1 (en) 2018-08-09
KR102679517B1 (ko) 2024-06-27
CN108137609A (zh) 2018-06-08
CA2994703A1 (en) 2017-02-09
EP3331889B1 (en) 2020-09-23
EA201890421A1 (ru) 2018-07-31
JP2018525377A (ja) 2018-09-06
CN108137609B (zh) 2021-07-16
AU2016301215A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
MX2018001173A (es) Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.
HK1252623A1 (zh) 可用作TNFα调节剂的杂环化合物
UA122498C2 (uk) Біциклічні похідні, спосіб їх отримання та фармацевтичні композиції, що їх містять
MX2017011433A (es) Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
UA118680C2 (uk) Похідні заміщеного гліоксамідом піроламіду та їхнє застосування як лікарських препаратів для лікування гепатиту в
MY190243A (en) Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX368845B (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MD4779B1 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX378435B (es) Administración específica del sitio de un inhibidor de btk.
MX2021003792A (es) Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
MX2017011577A (es) Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
GEAP201814401A (en) Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
MX374728B (es) MODULADORES DE ROR GAMMA (RORy).
EA201692480A1 (ru) Фармацевтическая композиция
MX377329B (es) Moduladores de ror gamma (ror?).
MX383592B (es) Moduladores de ror gamma (ror?).
MX2017011434A (es) Compuestos heterociclicos triciclicos sustituidos.
TW201613864A (en) Novel compounds
MD20170011A2 (ro) Compuşi imidazopiridazinici
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
MX378111B (es) Moduladores de ror gamma (ror?).
MX381129B (es) Inhibidores de dopamina-b-hidroxilasa.